Emerging to be a promising advance in the battle against obesity, Retatrutide is increasingly gaining focus. This novel dual activator – affecting both GLP-1 and GIP receptors – demonstrates remarkable effectiveness in research trials. Initial information suggest that Retatrutide could offer enhance